gas chromatography mass spectrometry gc ms system (Shimadzu Corporation)
Shimadzu Corporation is a verified supplier 
Shimadzu Corporation manufactures this product 
97
Structured Review
Shimadzu Corporation
gas chromatography mass spectrometry gc ms system
Gas Chromatography Mass Spectrometry Gc Ms System, supplied by Shimadzu Corporation, used in various techniques. Bioz Stars score: 97/100, based on 2479 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/GC+Systems/GCMS+NX+Series/pm42883327-213-7-14
Average 97 stars, based on 2479 article reviews
Gas Chromatography Mass Spectrometry Gc Ms System, supplied by Shimadzu Corporation, used in various techniques. Bioz Stars score: 97/100, based on 2479 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/GC+Systems/GCMS+NX+Series/pm42883327-213-7-14
Average 97 stars, based on 2479 article reviews
gas chromatography mass spectrometry gc ms system - by Bioz Stars,
2026-11
97/100 stars
Images
Related Articles
Solvent:Article Title: Design, Synthesis, and Characterization of Novel, Subtype-Selective Fluorescent Antagonists Targeting the Nociceptin/Orphanin FQ Opioid Peptide Receptor Article Snippet: Phenomenex C18 onyx monolithic columns were used for small scale RP-HPLC purifications (semipreparative 100 × 10 mm) and analytical HPLC analysis (100 × 4.6 mm). .. A Liquid Chromatography:Article Title: Design, Synthesis, and Characterization of Novel, Subtype-Selective Fluorescent Antagonists Targeting the Nociceptin/Orphanin FQ Opioid Peptide Receptor Article Snippet: Phenomenex C18 onyx monolithic columns were used for small scale RP-HPLC purifications (semipreparative 100 × 10 mm) and analytical HPLC analysis (100 × 4.6 mm). .. A Article Title: Discovery of the Clinical Candidate S‑892216 : A Second-Generation of SARS-CoV‑2 3CL Protease Inhibitor for Treating COVID-19 Article Snippet: .. Reactions were monitored via thin-layer chromatography performed on Merck silica gel plates (60 F254) or analytical LC/MS performed on ACQUITY UPLC BEH columns (C18, 1.7 μm, 2.1 × 50 mm, linear gradient from 5% to 100% B over 3.5 min, then 100% B for 0.5 min [A = water + 0.1% formic acid, B = MeCN + 0.1% formic acid], flow rate: 0.8 mL/min) using other:Article Title: Identification of specialized metabolites from Artocarpus lacucha as potent α-glucosidase and acetylcholinesterase inhibitors: enzyme kinetic, in vitro and in silico study. Article Snippet: Artocarpus species play an important role in the folk medicine of various ethnic groups in Africa, South Asia, and Southeast Asia.. In the present study, we investigated the potential of Artocarpus lacucha in the treatment of diabetes mellitus and Alzheimer’s disease.. During this work, one previously undescribed compound (1), along with 10 known compounds (2–11), were isolated from the leaves of Artocarpus lacucha. Thin Layer Chromatography:Article Title: Discovery of the Clinical Candidate S‑892216 : A Second-Generation of SARS-CoV‑2 3CL Protease Inhibitor for Treating COVID-19 Article Snippet: .. Reactions were monitored via thin-layer chromatography performed on Merck silica gel plates (60 F254) or analytical LC/MS performed on ACQUITY UPLC BEH columns (C18, 1.7 μm, 2.1 × 50 mm, linear gradient from 5% to 100% B over 3.5 min, then 100% B for 0.5 min [A = water + 0.1% formic acid, B = MeCN + 0.1% formic acid], flow rate: 0.8 mL/min) using Article Title: Discovery of the Clinical Candidate S-892216 : A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19. Article Snippet: .. Reactions were monitored via thin-layer chromatography performed on Merck silica gel plates (60 F254) or analytical LC/MS performed on ACQUITY UPLC BEH columns (C18, 1.7 μm, 2.1 × 50 mm, linear gradient from 5% to 100% B over 3.5 min, then 100% B for 0.5 min [A = water + 0.1% formic acid, B = MeCN + 0.1% formic acid], flow rate: 0.8 mL/min) using Liquid Chromatography with Mass Spectroscopy:Article Title: Discovery of the Clinical Candidate S‑892216 : A Second-Generation of SARS-CoV‑2 3CL Protease Inhibitor for Treating COVID-19 Article Snippet: .. Reactions were monitored via thin-layer chromatography performed on Merck silica gel plates (60 F254) or analytical LC/MS performed on ACQUITY UPLC BEH columns (C18, 1.7 μm, 2.1 × 50 mm, linear gradient from 5% to 100% B over 3.5 min, then 100% B for 0.5 min [A = water + 0.1% formic acid, B = MeCN + 0.1% formic acid], flow rate: 0.8 mL/min) using Article Title: Discovery of the Clinical Candidate S-892216 : A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19. Article Snippet: .. Reactions were monitored via thin-layer chromatography performed on Merck silica gel plates (60 F254) or analytical LC/MS performed on ACQUITY UPLC BEH columns (C18, 1.7 μm, 2.1 × 50 mm, linear gradient from 5% to 100% B over 3.5 min, then 100% B for 0.5 min [A = water + 0.1% formic acid, B = MeCN + 0.1% formic acid], flow rate: 0.8 mL/min) using Article Title: Metabolomic and transcriptomic signature in Kabuki syndrome Article Snippet: .. The C8-pos, C18-neg, and HILIC-pos methods were configured on Mass Spectrometry:Article Title: Discovery of the Clinical Candidate S‑892216 : A Second-Generation of SARS-CoV‑2 3CL Protease Inhibitor for Treating COVID-19 Article Snippet: .. Reactions were monitored via thin-layer chromatography performed on Merck silica gel plates (60 F254) or analytical LC/MS performed on ACQUITY UPLC BEH columns (C18, 1.7 μm, 2.1 × 50 mm, linear gradient from 5% to 100% B over 3.5 min, then 100% B for 0.5 min [A = water + 0.1% formic acid, B = MeCN + 0.1% formic acid], flow rate: 0.8 mL/min) using Article Title: Discovery of the Clinical Candidate S-892216 : A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19. Article Snippet: .. Reactions were monitored via thin-layer chromatography performed on Merck silica gel plates (60 F254) or analytical LC/MS performed on ACQUITY UPLC BEH columns (C18, 1.7 μm, 2.1 × 50 mm, linear gradient from 5% to 100% B over 3.5 min, then 100% B for 0.5 min [A = water + 0.1% formic acid, B = MeCN + 0.1% formic acid], flow rate: 0.8 mL/min) using Hydrophilic Interaction Liquid Chromatography:Article Title: Metabolomic and transcriptomic signature in Kabuki syndrome Article Snippet: .. The C8-pos, C18-neg, and HILIC-pos methods were configured on |